Medical products company UFP Technologies (NASDAQ: UFPT) will be reporting earnings this Tuesday after market hours. Here’s what to look for.
UFP Technologies beat analysts’ revenue expectations last quarter, reporting revenues of $154.6 million, up 6.5% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.
Is UFP Technologies a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting UFP Technologies’s revenue to grow 3.5% year on year, slowing from the 41.9% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. UFP Technologies rarely misses Wall Street’s revenue estimates.
Looking at UFP Technologies’s peers in the drug development inputs & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 32%, beating analysts’ expectations by 3.3%, and West Pharmaceutical Services reported revenues up 7.5%, topping estimates by 1.5%. Medpace traded down 15.9% following the results while West Pharmaceutical Services was up 1.8%.
Read our full analysis of Medpace’s results here and West Pharmaceutical Services’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the drug development inputs & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. UFP Technologies is down 6.2% during the same time and is heading into earnings with an average analyst price target of $329.50 (compared to the current share price of $231.69).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
